TY - JOUR
T1 - ICOSL: more than a trigger of ICOS function
AU - Stoppa, Ian
AU - Provera, Alessia
AU - Sacchetti, Sara
AU - Clemente, Nausicaa
AU - Pantham, Deepika
AU - Christaki, Foteini
AU - Vecchio, Cristina
AU - Sheferaw, Anteneh Nigussie
AU - ROLLA, Roberta
AU - Dianzani, Chiara
AU - SUTTI, Salvatore
AU - DIANZANI, Umberto
PY - 2025
Y1 - 2025
N2 - : Inducible T-cell costimulator (ICOS) and its ligand ICOSL are members of the CD28 and B7 receptor families that play central roles in immune regulation. While the role of ICOS in T-cell activation and differentiation has been widely studied, increasing evidence indicates that ICOSL, which is broadly expressed across both immune and nonimmune cell types, also functions as a signaling receptor. This review focuses on ICOSL-mediated reverse signaling and its ability to modulate the behavior of ICOSL-expressing immune and stromal cells. In vitro, ICOSL activation induces cell type-specific responses, most notably regulating cell migration. In vivo, ICOSL signaling influences key processes such as tumor growth, bone remodeling, wound healing, liver regeneration, and sepsis. Taken together, these findings expand the conventional view of ICOSL as a passive ligand and suggest that ICOSL is a versatile immune modulator with therapeutic relevance in cancer, inflammatory, and fibrotic diseases.
AB - : Inducible T-cell costimulator (ICOS) and its ligand ICOSL are members of the CD28 and B7 receptor families that play central roles in immune regulation. While the role of ICOS in T-cell activation and differentiation has been widely studied, increasing evidence indicates that ICOSL, which is broadly expressed across both immune and nonimmune cell types, also functions as a signaling receptor. This review focuses on ICOSL-mediated reverse signaling and its ability to modulate the behavior of ICOSL-expressing immune and stromal cells. In vitro, ICOSL activation induces cell type-specific responses, most notably regulating cell migration. In vivo, ICOSL signaling influences key processes such as tumor growth, bone remodeling, wound healing, liver regeneration, and sepsis. Taken together, these findings expand the conventional view of ICOSL as a passive ligand and suggest that ICOSL is a versatile immune modulator with therapeutic relevance in cancer, inflammatory, and fibrotic diseases.
KW - Angiogenesis
KW - Immune checkpoints
KW - Reverse signalling
KW - Tumor microenvironment
KW - Angiogenesis
KW - Immune checkpoints
KW - Reverse signalling
KW - Tumor microenvironment
UR - https://iris.uniupo.it/handle/null
U2 - 10.1186/s12964-025-02559-4
DO - 10.1186/s12964-025-02559-4
M3 - Article
SN - 1478-811X
JO - Cell Communication and Signaling
JF - Cell Communication and Signaling
ER -